Athersys stem-cell therapy for bowel disease fails in study

April 28 Mon Apr 28, 2014 7:18am EDT

April 28 (Reuters) - Athersys Inc said its experimental stem-cell therapy for treating an inflammatory bowel disease failed to show any benefit in patients in a mid-stage trial.

The trial, conducted by Athersys's partner Pfizer Inc , did not show a statistically significant reduction in the severity of the disease and rectal bleeding as compared to placebo. (Reporting by Esha Dey in Bangalore; Editing by Saumyadeb Chakrabarty)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.